Abstract
Preimplantation genetic screening (PGS) intends to improve reproductive outcome through selecting euploid embryos by chromosomal analysis on cleavage-stage embryos. The main indication is subfertility in couples with advanced maternal age. PGS is also advocated as a tool to improve the live-birth rate in couples with repeated implantation failure, repeated miscarriage or severe male factor infertility. The use of PGS in couples with advanced maternal age has only been evaluated in three randomized, controlled trials to date. However, these studies did not demonstrate a significantly higher live-birth rate or lower miscarriage rate with this technique. Moreover, no large, randomized clinical trials have been published on PGS indications other than advanced maternal age. Limitations of the technique include a possible inaccurate chromosomal analysis of the blastomere and embryonic mosaicism. We conclude that there is no place for the routine clinical use of PGS.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.